Proceedings of the National Academy of Sciences · 2012 · 88 citations · 18 references
Public HealthHealth PolicyPharmacoeconomicsCost-effectiveness AnalysisGlobal HealthHiv PreventionAntiretroviral TherapyDisease ControlHiv EpidemiologyTreatment As PreventionAntiretroviral Therapy CoverageCombination Hiv PreventionHiv Incidence Reduction TrialsHiv Prevention EffectivenessHiv Transmission DynamicsHiv Transmission ReductionPrevention TrialsTreatment As Prevention Modeling
The HIV Prevention Trials Network (HPTN) 052 study, which showed the effectiveness of antiretroviral treatment in reducing HIV transmission, has been hailed as a "game changer" in the fight against HIV, prompting calls for scaling up treatment as prevention (TasP). However, it is unclear how TasP can be financed, given flat-lining support for global HIV programs. We assess whether TasP is indeed a game changer or if comparable benefits are obtainable at similar or lower cost by increasing coverage of medical male circumcision (MMC) and antiretroviral treatment (ART) at CD4 <350/μL. We develop a new mathematical model and apply it to South Africa, finding that high ART coverage combined with high MMC coverage provides approximately the same HIV incidence reduction as TasP, for $5 billion less over 2009-2020. MMC outperforms ART significantly in cost per infection averted ($1,096 vs. $6,790) and performs comparably in cost per death averted ($5,198 vs. $5,604). TasP is substantially less cost effective at $8,375 per infection and $7,739 per death averted. The prevention benefits of HIV treatment are largely reaped with high ART coverage. The most cost-effective HIV prevention strategy is to expand MMC coverage and then scale up ART, but the most cost-effective HIV-mortality reduction strategy is to scale up MMC and ART jointly. TasP is cost effective by commonly used absolute benchmarks but it is far less cost effective than MMC and ART. Given South Africa's current annual ART spending, the $5 billion in savings offered by MMC and ART over TasP in the next decade, for similar health benefits, challenges the widely hailed status of TasP as a game changer.
18
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
Ronald H. Gray, Godfrey Kigozi, David Serwadda et al. · The Lancet · 2007 · 2.2K citations